Who owns DELCATH SYSTEMS, INC. (DCT)? Elite investor 13F holders
2 tracked elite investors reported holding DELCATH SYSTEMS, INC as of 2026-06-30, including D.E. Shaw, Tudor Investment. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.
2 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Health Care Equipment & Services
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development…
Reported holders and securities, including exits (up to 20)
| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|---|---|---|---|---|---|---|---|---|---|
| Renaissance Technologies LLC | DELCATH SYS INC | SHARE | 2026-06-30 | 2026-08-13 00:00:00 | 0.00 USD | 0.000000 | Shares | exited | Original filing |
| D.E. Shaw | DELCATH SYS INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 728885.00 USD | 57894.000000 | Shares | buy | Original filing |
| Tudor Investment | DELCATH SYS INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 151609.00 USD | 12042.000000 | Shares | reduce | Original filing |
Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.
This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.